Compare MDV & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDV | MDWD |
|---|---|---|
| Founded | 2015 | 2000 |
| Country | United States | Israel |
| Employees | 9 | N/A |
| Industry | Transportation Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.5M | 181.1M |
| IPO Year | N/A | 2013 |
| Metric | MDV | MDWD |
|---|---|---|
| Price | $18.00 | $14.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $18.00 | ★ $36.00 |
| AVG Volume (30 Days) | 55.5K | ★ 114.6K |
| Earning Date | 05-08-2026 | 05-20-2026 |
| Dividend Yield | ★ 7.50% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $48.92 |
| Revenue Next Year | $8.56 | $35.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.80 | $13.54 |
| 52 Week High | $18.83 | $21.26 |
| Indicator | MDV | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 50.81 | 41.34 |
| Support Level | $17.60 | $13.54 |
| Resistance Level | $18.75 | $14.99 |
| Average True Range (ATR) | 0.37 | 0.52 |
| MACD | -0.13 | 0.08 |
| Stochastic Oscillator | 30.33 | 35.98 |
Modiv Industrial Inc is a pioneer in the direct-to-consumer commercial real estate product industry. It provides individual investors access to real estate and real estate-related investments designed to provide both income and long-term growth. The company has invested in single-tenant income-producing properties. Its current business consists of owning, managing, operating, leasing, acquiring, investing in, and disposing of commercial real estate assets utilized for industrial manufacturing, as well as a few non-core assets. All of the company's consolidated revenues are derived from the company's consolidated real estate properties.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.